Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

Canaccord Genuity's Edward Nash raised their price target on Travere Therapeutics (NASDAQ: TVTX) by 12.9% from $62 to $70 on 2026/08/07. The analyst maintained their Strong Buy rating on the stock.

Travere Therapeutics reported its Q2 2026 earnings.

Raising their price target, Nash headlined that Filspari product revenue came in at $141.1M, 34.2% sequential growth.

Looking ahead, the analyst told readers that management highlighted a strong early launch in FSGS and reiterated its confidence in the $3B+ peak sales projection for Filspari across both indications.

Earnings Report

For Q2 2026, Travere Therapeutics reported:

• EPS of $(0.37), which missed the Zacks Consensus Estimate and Q2 2025, both $(0.14).
• Revenue of $169.58M, which beat the Zacks Consensus Estimate by 10.16% and Q2 2025's $114.45M.

Management did not provide financial guidance in its press release.

President & CEO Eric Dube, Ph.D., commented: “With an exceptional second quarter, Travere has entered a new chapter of near- and long-term growth.

“Our performance reflects the strength of the company we are building and the disciplined execution of our teams as we continue to deliver on our strategy.

"During the quarter, we made meaningful progress across each of our strategic growth pillars, driving continued commercial momentum for FILSPARI, including a promising early launch in FSGS and continued strength in IgA nephropathy, as well as advancing our pegtibatinase program toward its pivotal Phase 3 readout and expanding our rare kidney disease pipeline through the addition of civorebrutinib.

"Together, these strengthen the durability of our growth profile, diversify our pipeline and reinforce our commitment to delivering meaningful new therapies for people living with rare diseases.”